GO
Loading...

A Rare Failure For Roche's Avastin

It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange"at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer. This was a highly anticipated clinical trial report.

Analysts had forecast that if the drug worked well in this test it could have added several hundred million dollars, maybe even billions, to Avastin's annual revenue. The thinking was that the read-through by oncologists would have been that the drug might also work in early stages of other cancers and start using Avastin on those tumors as well. But they'll have to wait. The companies say they're still confident Avastin might work on early stage colon cancer and they're continuing with eight other studies testing the drug in the early stages of different tumors.

Nonetheless, shares of the Swiss drugmaker Roche are getting hammered in overseas trading. They're only sold over the counter in the US.

When Roche was chasing Genentech a lot of people speculated the company was in a hurry to get the deal done before these results came out. The purported fear was if the drug worked Genentech's stock price would soar and possibly put the company out of Roche's price range. Some even floated the idea that Roche had an inkling the study might be positive and, therefore, it was in a rush to come to terms with DNA. This, I think, proves those speculators wrong. I even wonder whether Roche might be kicking itself now for not having the chutzpah to roll the dice and wait until these results came in. Maybe it could've picked up Genentech on the cheap. Analysts thought DNA shares would've tanked if the test turned out this way.

Interestingly, a Genentech spokesperson says the company's President of Product Development, Dr. Susan Desmond-Hellmann won't be available for a CNBC interview today. When test results have gone their way (and that's more often than not), she has almost always come on our air first thing in the morning to take a victory lap. Not this time. Maybe it's because she'll soon be relegated to an advisory role or maybe Roche is calling the shots now and she doesn't have much of a say in the media strategy anymore. But this was a Genentech study, not a Roche study. This was Dr. Hellmann's baby. After a tremendous string of successful clinical trials, it's a shame she couldn't go out with another big win.

But, as I know she'd be the first to say, the biggest disappointment here is for patients.

Questions? Comments? Pharma@cnbc.com and follow me on Twitter at mhuckman

Symbol
Price
 
Change
%Change
ROG
---